EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression - Concepedia

Concepedia

Publication | Open Access

EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression

DOI Full Paper Access

126

Citations

35

References

2020

Year

Stéphanie Lheureux, Ana Oaknin, Swati Garg, Jeffrey P. Bruce, Ainhoa Madariaga, Neesha C. Dhani, Valerie Bowering, Justin White, Sarah Accardi, Qian Tan,

Clinical Cancer Research

Abstract

This is currently the largest post-PARPi study identifying genomic mechanisms of resistance to PARPis. In this setting, the activity of cediranib-olaparib varied according to the PARPi resistance mechanism.

References

	Year	Citations

Page 1